Skip to main content
Erschienen in: Diagnostic Pathology 1/2013

Open Access 01.12.2013 | Research

Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors

verfasst von: Konstantin Shilo, Xin Wu, Smita Sharma, Meng Welliver, Wenrui Duan, Miguel Villalona-Calero, Junya Fukuoka, Said Sif, Robert Baiocchi, Charles L Hitchcock, Weiqiang Zhao, Gregory A Otterson

Erschienen in: Diagnostic Pathology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Protein arginine methyltransferase-5 (PRMT5) is a chromatin-modifying enzyme capable of methylating histone and non-histone proteins, and is involved in a wide range of cellular processes that range from transcriptional regulation to organelle biosynthesis. As such, its overexpression has been linked to tumor suppressor gene silencing, enhanced tumor cell growth and survival.

Material and methods

Quantitative real-time polymerase chain reaction, Western immunoblot and immunohistochemistry were used to characterize PRMT5 expression in lung cancer cell lines and human tumors. Clinicopathological findings of tissue microarray based samples from 229 patients with non-small cell lung carcinomas (NSCLC) and 133 cases with pulmonary neuroendocrine tumors (NET) were analyzed with regard to nuclear and cytoplasmic PRMT5 expression.

Results

There was statistically significant difference in PRMT5 messenger RNA expression between tumors and nonneoplastic lung tissues. Immunoblot experiments showed abundant expression of PRMT5 and its symmetric methylation mark H4R3 in lung carcinoma but not in non-neoplastic human pulmonary alveolar and bronchial epithelial cell lines. More than two thirds of lung tumors expressed PRMT5. High levels of cytoplasmic PRMT5 were detected in 20.5% of NSCLC and in 16.5% of NET; high levels of nuclear PRMT5 were detected in 38.0% of NSCLC and 24.0% of NET. Cytoplasmic PRMT5 was associated with high grade in both NSCLC and pulmonary NET while nuclear PRMT5 was more frequent in carcinoid tumors (p < 0.05).

Conclusion

The observed findings support the role of PRMT5 in lung tumorigenesis and reflect its functional dichotomy in cellular compartments.

Virtual slide

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed
2.
Zurück zum Zitat D’Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG: Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011, 29 (15): 2066-2070. 10.1200/JCO.2010.32.6181.PubMedCentralCrossRefPubMed D’Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG: Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011, 29 (15): 2066-2070. 10.1200/JCO.2010.32.6181.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, Riggs AD, Pfeifer GP: High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA. 2008, 105 (1): 252-257. 10.1073/pnas.0710735105.PubMedCentralCrossRefPubMed Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, Riggs AD, Pfeifer GP: High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA. 2008, 105 (1): 252-257. 10.1073/pnas.0710735105.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012, 489 (7417): 519-525. 10.1038/nature11404.CrossRef Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012, 489 (7417): 519-525. 10.1038/nature11404.CrossRef
5.
Zurück zum Zitat Vaitkiene P, Skiriute D, Skauminas K, Tamasauskas A: GATA4 and DcR1 methylation in glioblastomas. Diagn Pathol. 2013, 8: 7-10.1186/1746-1596-8-7.PubMedCentralCrossRefPubMed Vaitkiene P, Skiriute D, Skauminas K, Tamasauskas A: GATA4 and DcR1 methylation in glioblastomas. Diagn Pathol. 2013, 8: 7-10.1186/1746-1596-8-7.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Guzman L, Depix MS, Salinas AM, Roldan R, Aguayo F, Silva A, Vinet R: Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: a promising tool for early detection of COPD and lung cancer in smokers. Diagn Pathol. 2012, 7: 87-10.1186/1746-1596-7-87.PubMedCentralCrossRefPubMed Guzman L, Depix MS, Salinas AM, Roldan R, Aguayo F, Silva A, Vinet R: Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: a promising tool for early detection of COPD and lung cancer in smokers. Diagn Pathol. 2012, 7: 87-10.1186/1746-1596-7-87.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, et al.: DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001, 1 (1): 61-67.PubMed Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, et al.: DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001, 1 (1): 61-67.PubMed
8.
Zurück zum Zitat Ji M, Zhang Y, Shi B, Hou P: Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn Pathol. 2011, 6: 48-10.1186/1746-1596-6-48.PubMedCentralCrossRefPubMed Ji M, Zhang Y, Shi B, Hou P: Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn Pathol. 2011, 6: 48-10.1186/1746-1596-6-48.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995, 55 (20): 4525-4530.PubMed Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995, 55 (20): 4525-4530.PubMed
10.
Zurück zum Zitat Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ: CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene. 1995, 11 (6): 1211-1216.PubMed Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ: CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene. 1995, 11 (6): 1211-1216.PubMed
11.
Zurück zum Zitat Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A: Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000, 18 (5): 956-962.PubMed Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A: Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000, 18 (5): 956-962.PubMed
12.
Zurück zum Zitat Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002, 20 (10): 2429-2440. 10.1200/JCO.2002.04.117.CrossRefPubMed Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002, 20 (10): 2429-2440. 10.1200/JCO.2002.04.117.CrossRefPubMed
13.
Zurück zum Zitat Bedford MT, Richard S: Arginine methylation an emerging regulator of protein function. Mol Cell. 2005, 18 (3): 263-272. 10.1016/j.molcel.2005.04.003.CrossRefPubMed Bedford MT, Richard S: Arginine methylation an emerging regulator of protein function. Mol Cell. 2005, 18 (3): 263-272. 10.1016/j.molcel.2005.04.003.CrossRefPubMed
14.
Zurück zum Zitat Pal S, Sif S: Interplay between chromatin remodelers and protein arginine methyltransferases. J Cell Physiol. 2007, 213 (2): 306-315. 10.1002/jcp.21180.CrossRefPubMed Pal S, Sif S: Interplay between chromatin remodelers and protein arginine methyltransferases. J Cell Physiol. 2007, 213 (2): 306-315. 10.1002/jcp.21180.CrossRefPubMed
15.
Zurück zum Zitat Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S: Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004, 24 (21): 9630-9645. 10.1128/MCB.24.21.9630-9645.2004.PubMedCentralCrossRefPubMed Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S: Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004, 24 (21): 9630-9645. 10.1128/MCB.24.21.9630-9645.2004.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Wang L, Pal S, Sif S: Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol. 2008, 28 (20): 6262-6277. 10.1128/MCB.00923-08.PubMedCentralCrossRefPubMed Wang L, Pal S, Sif S: Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol. 2008, 28 (20): 6262-6277. 10.1128/MCB.00923-08.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Gu Z, Gao S, Zhang F, Wang Z, Ma W, Davis RE: Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J. 2012, 446 (2): 235-241. 10.1042/BJ20120768.CrossRefPubMed Gu Z, Gao S, Zhang F, Wang Z, Ma W, Davis RE: Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J. 2012, 446 (2): 235-241. 10.1042/BJ20120768.CrossRefPubMed
18.
Zurück zum Zitat Gu Z, Li Y, Lee P, Liu T, Wan C, Wang Z: Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One. 2012, 7 (8): e44033-10.1371/journal.pone.0044033.PubMedCentralCrossRefPubMed Gu Z, Li Y, Lee P, Liu T, Wan C, Wang Z: Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One. 2012, 7 (8): e44033-10.1371/journal.pone.0044033.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Karkhanis V, Wang L, Tae S, Hu YJ, Imbalzano AN, Sif S: Protein arginine methyltransferase 7 regulates cellular response to DNA damage by methylating promoter histones H2A and H4 of the polymerase delta catalytic subunit gene, POLD1. J Biol Chem. 2012, 287 (35): 29801-29814. 10.1074/jbc.M112.378281.PubMedCentralCrossRefPubMed Karkhanis V, Wang L, Tae S, Hu YJ, Imbalzano AN, Sif S: Protein arginine methyltransferase 7 regulates cellular response to DNA damage by methylating promoter histones H2A and H4 of the polymerase delta catalytic subunit gene, POLD1. J Biol Chem. 2012, 287 (35): 29801-29814. 10.1074/jbc.M112.378281.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Friesen WJ, Paushkin S, Wyce A, Massenet S, Pesiridis GS, Van Duyne G, Rappsilber J, Mann M, Dreyfuss G: The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. Mol Cell Biol. 2001, 21 (24): 8289-8300. 10.1128/MCB.21.24.8289-8300.2001.PubMedCentralCrossRefPubMed Friesen WJ, Paushkin S, Wyce A, Massenet S, Pesiridis GS, Van Duyne G, Rappsilber J, Mann M, Dreyfuss G: The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. Mol Cell Biol. 2001, 21 (24): 8289-8300. 10.1128/MCB.21.24.8289-8300.2001.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Friesen WJ, Wyce A, Paushkin S, Abel L, Rappsilber J, Mann M, Dreyfuss G: A novel WD repeat protein component of the methylosome binds Sm proteins. J Biol Chem. 2002, 277 (10): 8243-8247. 10.1074/jbc.M109984200.CrossRefPubMed Friesen WJ, Wyce A, Paushkin S, Abel L, Rappsilber J, Mann M, Dreyfuss G: A novel WD repeat protein component of the methylosome binds Sm proteins. J Biol Chem. 2002, 277 (10): 8243-8247. 10.1074/jbc.M109984200.CrossRefPubMed
22.
Zurück zum Zitat Antonysamy S, Bonday Z, Campbell RM, Doyle B, Druzina Z, Gheyi T, Han B, Jungheim LN, Qian Y, Rauch C, et al.: Crystal structure of the human PRMT5:MEP50 complex. Proc Natl Acad Sci USA. 2012, 109 (44): 17960-17965. 10.1073/pnas.1209814109.PubMedCentralCrossRefPubMed Antonysamy S, Bonday Z, Campbell RM, Doyle B, Druzina Z, Gheyi T, Han B, Jungheim LN, Qian Y, Rauch C, et al.: Crystal structure of the human PRMT5:MEP50 complex. Proc Natl Acad Sci USA. 2012, 109 (44): 17960-17965. 10.1073/pnas.1209814109.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Fukuoka J, Dracheva T, Shih JH, Hewitt SM, Fujii T, Kishor A, Mann F, Shilo K, Franks TJ, Travis WD, et al.: Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol. 2007, 38 (2): 276-283. 10.1016/j.humpath.2006.08.006.CrossRefPubMed Fukuoka J, Dracheva T, Shih JH, Hewitt SM, Fujii T, Kishor A, Mann F, Shilo K, Franks TJ, Travis WD, et al.: Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol. 2007, 38 (2): 276-283. 10.1016/j.humpath.2006.08.006.CrossRefPubMed
24.
Zurück zum Zitat Shilo K, Dracheva T, Mani H, Fukuoka J, Sesterhenn IA, Chu WS, Shih JH, Jen J, Travis WD, Franks TJ: Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis. Arch Pathol Lab Med. 2007, 131 (10): 1555-1560.PubMed Shilo K, Dracheva T, Mani H, Fukuoka J, Sesterhenn IA, Chu WS, Shih JH, Jen J, Travis WD, Franks TJ: Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis. Arch Pathol Lab Med. 2007, 131 (10): 1555-1560.PubMed
25.
Zurück zum Zitat Espino PS, Drobic B, Dunn KL, Davie JR: Histone modifications as a platform for cancer therapy. J Cell Biochem. 2005, 94 (6): 1088-1102. 10.1002/jcb.20387.CrossRefPubMed Espino PS, Drobic B, Dunn KL, Davie JR: Histone modifications as a platform for cancer therapy. J Cell Biochem. 2005, 94 (6): 1088-1102. 10.1002/jcb.20387.CrossRefPubMed
26.
27.
Zurück zum Zitat Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS: Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 2011, 71 (16): 5579-5587. 10.1158/0008-5472.CAN-11-0458.PubMedCentralCrossRefPubMed Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS: Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 2011, 71 (16): 5579-5587. 10.1158/0008-5472.CAN-11-0458.PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R, et al.: Arginine methylation controls growth regulation by E2F-1. Embo J. 2012, 31 (7): 1785-1797. 10.1038/emboj.2012.17.PubMedCentralCrossRefPubMed Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R, et al.: Arginine methylation controls growth regulation by E2F-1. Embo J. 2012, 31 (7): 1785-1797. 10.1038/emboj.2012.17.PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Lu Q, Li N, Luo J, Yu M, Huang Y, Wu X, Wu H, Liu XY, Li G: Pinellia pedatisecta agglutinin interacts with the methylosome and induces cancer cell death. Oncogenesis. 2012, 1: e29-10.1038/oncsis.2012.30.PubMedCentralCrossRefPubMed Lu Q, Li N, Luo J, Yu M, Huang Y, Wu X, Wu H, Liu XY, Li G: Pinellia pedatisecta agglutinin interacts with the methylosome and induces cancer cell death. Oncogenesis. 2012, 1: e29-10.1038/oncsis.2012.30.PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Gradowski JF, Mantha GS, Hunt JL, Dacic S: Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs. Diagn Mol Pathol. 2007, 16 (2): 87-90. 10.1097/PDM.0b013e318030afde.CrossRefPubMed Gradowski JF, Mantha GS, Hunt JL, Dacic S: Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs. Diagn Mol Pathol. 2007, 16 (2): 87-90. 10.1097/PDM.0b013e318030afde.CrossRefPubMed
31.
Zurück zum Zitat Kayser K, Kosjerina Z, Goldmann T, Kayser G, Kazmierczak B, Vollmer E: Lung carcinoma-associated atypical adenomatoid hyperplasia, squamous cell dysplasia, and chromosome alterations in non-neoplastic bronchial mucosa. Lung Cancer. 2005, 47 (2): 205-214. 10.1016/j.lungcan.2004.07.042.CrossRefPubMed Kayser K, Kosjerina Z, Goldmann T, Kayser G, Kazmierczak B, Vollmer E: Lung carcinoma-associated atypical adenomatoid hyperplasia, squamous cell dysplasia, and chromosome alterations in non-neoplastic bronchial mucosa. Lung Cancer. 2005, 47 (2): 205-214. 10.1016/j.lungcan.2004.07.042.CrossRefPubMed
32.
Zurück zum Zitat Bao X, Zhao S, Liu T, Liu Y, Yang X: Overexpression PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem. 2013, 61 (3): 206-217. 10.1369/0022155413475452.PubMedCentralCrossRefPubMed Bao X, Zhao S, Liu T, Liu Y, Yang X: Overexpression PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem. 2013, 61 (3): 206-217. 10.1369/0022155413475452.PubMedCentralCrossRefPubMed
Metadaten
Titel
Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors
verfasst von
Konstantin Shilo
Xin Wu
Smita Sharma
Meng Welliver
Wenrui Duan
Miguel Villalona-Calero
Junya Fukuoka
Said Sif
Robert Baiocchi
Charles L Hitchcock
Weiqiang Zhao
Gregory A Otterson
Publikationsdatum
01.12.2013
Verlag
BioMed Central
Erschienen in
Diagnostic Pathology / Ausgabe 1/2013
Elektronische ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-201

Weitere Artikel der Ausgabe 1/2013

Diagnostic Pathology 1/2013 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …